Please use this identifier to cite or link to this item:
|Title:||Comparison between a point-of-care and a laboratory-based CYP2C19*2 genotyping assay for pharmacist-led personalisation of antiplatelet therapy|
Xuereb, Robert G.
Azzopardi, Lilian M.
|Keywords:||Blood platelet disorders|
Blood platelets -- Aggregation
Coronary arteries -- Stenosis
Cytochrome P-450 CYP2C19
Pharmacists -- Practice
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Wirth, F., Zahra, G., Xuereb, R. G., Barbara, C., Fenech, A., & Azzopardi, L. M. (2015, October). Comparison between a point-of-care and a laboratory-based CYP2C19*2 genotyping assay for pharmacist-led personalisation of antiplatelet therapy. Poster session presented at the ACCP Global Conference on Clinical Pharmacy, San Francisco, USA.|
|Abstract:||A poster presentation regarding a comparison between a point-of-care and a laboratory-based CYP2C19*2 genotyping assay for pharmacist-led personalisation of antiplatelet therapy. Introduction: The novel point-of-care (POC) Spartan™ RX CYP2C19 genotyping assay rapidly identifies presence of the CYP2C19 loss-offunction ‘*2’ variant allele and can be applied to personalise antiplatelet therapy at the start of treatment. This POC assay has not been previously compared to laboratory-based CYP2C19*2 genotyping using reverse dot-blot (RDB) hybridisation. Aims: To apply the Spartan™ RX assay for pharmacist-led CYP2C19*2 genotyping to personalise antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) and compare it to a laboratory-based CYP2C19*2 genotyping assay which uses a robust and accurate RDB hybridisation technique.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|Comparison_between_a_point_of_care_and_a_laboratory_based_CYP2C19_2_genotyping_assay_2015.pdf||549.98 kB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.